摘要
年龄相关性黄斑变性(AMD)是50岁以上老年人重要致盲眼病。血管内皮生长因子(VEGF)与湿性AMD发生发展密切相关,目前主要采用针对VEGF的单克隆抗体药物治疗,但维持时间短,需要频繁、重复治疗。随着基因治疗的发展,可能作为生物标志物的可溶性血管内皮生长因子受体-1(s Flt-1)逐渐受到关注。s Flt-1是目前发现唯一的内源性VEGF抑制剂。在AMD发展过程中,患者血清s Flt-1水平明显降低。该文就近年来有关s Flt-1的分子结构、病理生理学功能、在AMD发生发展中的作用、临床前研究及临床研究进行综述。
Age-related macular degeneration （AMD） is the leading cause of blindness in people over 50 years old. Vascular endothelial growth factor （VEGF） plays a critical role in the development of wet AMD. At present, the main treatment is monoclonal antibodies against VEGF, but the maintenance time is short, and it requires frequent and repeated treatment. Recently with the fast development of gene therapy, soluble VEGF receptor -1 （sFlt-1）, which may act as one of the biomarkers of AMD, is gaining more attention, sFlt-1 is the unique endogenous VEGF inhibitor. With the development of AMD, serum sFlt-1 decreases markedly. This article reviewed the molecular sWucture and pathophysiotogical function of sFlt-1, its role in the advance of AMD, and the preclinical studies as well as clinical studies about it.
出处
《上海交通大学学报（医学版）》
CSCD
北大核心
2017年第9期1296-1302,共7页
Journal of Shanghai Jiao tong University:Medical Science
基金
国家自然科学基金(81300820)
上海市教育委员会高峰高原学科建设计划(20152229)~~
